In ADPKD, treatment with a glutaminase inhibitor in PKD1-mutant mice, both in utero and postnatally, resulted in slowed cyst progression, highlighting the potential therapeutic benefit of targeting glutamine metabolism in ADPKD [40]. Here, PKD1 is linked to autosomal dominant polycystic kidney disease.